Pharmaceutical Drugs of Uncertain Value, Lifecycle Reg
Administration, and Institutional Incumbency

Milbank Quarterly

97, 820-857

DOI: 10.1111/1468-0009.12413

Citation Report

#	Article	IF	Citations
1	Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States. Milbank Quarterly, 2020, 98, 1219-1256.	2.1	37
2	Communicating emerging risks of SGLT2 inhibitorsâ€"timeliness and transparency of medicine regulators. BMJ, The, 2020, 369, m1107.	3.0	7
3	Generating comparative evidence on new drugs and devices after approval. Lancet, The, 2020, 395, 998-1010.	6.3	52
4	Generating comparative evidence on new drugs and devices before approval. Lancet, The, 2020, 395, 986-997.	6.3	59
5	Ethical implications of poor comparative effectiveness evidence: obligations in industry-research partnerships. Lancet, The, 2020, 395, 926-928.	6.3	6
6	Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. Clinical Pharmacology and Therapeutics, 2021, 109, 1424-1442.	2.3	12
7	Industry, experts and the role of the â€˜invisible collegeâ€™ in the dissemination of non-invasive prenatal testing in the US. Social Science and Medicine, 2021, 270, 113635.	1.8	8
8	US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009â€"2018. Clinical Trials, 2021, 18, 488-499.	0.7	13
9	Exploring the Food and Drug Administrationâ€™s review and approval of Entresto (sacubitril/valsartan). Pharmacology Research and Perspectives, 2021, 9, e00794.	1.1	8
10	Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. BMJ, The, 2021, 374, n1959.	3.0	40
12	Use of data from the Vascular Quality Initiative registry to support regulatory decisions yielded a high return on investment. BMJ Surgery, Interventions, and Health Technologies, 2020, 2, e000039.	0.6	8
13	Section 5: Regulation and Governance. , 2020, , 229-295.		0
15	Challenges in confirming drug effectiveness after early approval. Science, 2021, 374, 1205-1207.	6.0	11
16	Conditional Drug Approval as a Path to Market for Oncology Drugs in Canada: Challenges and Recommendations for Assessing Eligibility and Regulatory Responsiveness. Frontiers in Medicine, 2021, 8, 818647.	1.2	7
17	New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence. Drug Safety, 2022, 45, 305-318.	1.4	7
18	The Importance of and Challenges with Adopting Life-Cycle Regulation and Reimbursement in Canada. Healthcare Policy, 2022, 17, 81-90.	0.3	0
19	Financial conflicts of interest during meetings of the cardiovascular and renal drugs advisory committee. Journal of Osteopathic Medicine, 2022, .	0.4	0
20	Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020. JAMA Network Open, 2022, 5, e2212454.	2.8	11

#	Article	IF	Citations
21	Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017. JAMA Health Forum, 2022, 3, e221158.	1.0	3
22	Is regulatory innovation fit for purpose? A case study of adaptive regulation for advanced biotherapeutics. Regulation and Governance, 0, , .	1.9	0
23	Association Between Preapproval Confirmatory Trial Initiation and Conversion to Traditional Approval or Withdrawal in the FDA Accelerated Approval Pathway. JAMA - Journal of the American Medical Association, 2023, 329, 760.	3.8	7
24	Faster UK drug approvals by relying on other countries. BMJ, The, 0, , p739.	3.0	1
25	Measure of Value: FDA in the Age of COVID. , 2022, 10, 1-14.		0